More than a third of high-risk leukemia patients respond to an experimental new drug

A new drug for patients with acute myeloid leukemia marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial.

http://www.innovations-report.com/html/reports/medicine_health/a_high_risk_leukemia_patients_respond_experimental_206931.html